HCM - CIK 0001648257
HUTCHMED (China) Ltd trades as HCM and has a market capitalization of $2.08 B, making it the #2073 largest US-listed company by market value. In its fiscal 2025 annual report the company posted revenue of $548.51M, down 13.0% from the prior year and net income of $456.91M. This page tracks HUTCHMED (China) Ltd through 589 SEC filings, with financial statements and metrics updated as new reports are filed.
Over the last 9 fiscal years HUTCHMED (China) Ltd's revenue grew from $216.08M to $548.51M, a compound annual growth rate of 10.9%. Net profit margin expanded from 5.4% to 83.3% over the same period - every figure below comes from the company's audited annual filings.
| Filing | Type | Filed |
|---|---|---|
| 6-K | - | 2026-05-22 |
| 6-K | - | 2026-05-21 |
| Insider trade | 4 | 2026-05-21 |
| Insider trade | 4 | 2026-05-21 |
| Insider trade | 4 | 2026-05-21 |
| Insider trade | 4 | 2026-05-21 |
| Insider trade | 4 | 2026-05-13 |
| 6-K | - | 2026-05-12 |
The largest companies sharing HUTCHMED (China) Ltd's SEC industry classification (pharmaceutical preparations).
HUTCHMED (China) Ltd (HCM) has a market capitalization of $2.08 B as of 2026-05-29, ranking #2073 among US-listed companies.
HUTCHMED (China) Ltd reported revenue of $548.51M for fiscal year 2025, a decrease of 13.0% year over year.
Yes. HUTCHMED (China) Ltd reported net income of $456.91M in its latest fiscal year.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
Dig into the full income statement, balance sheet, and cash flow statement with annual and quarterly views.